General Concept. LWP with the collaboration of CIM will implement the CIM Talk City Service and the CIM OnNow Service, which CIM will then integrate into select
General Concept. CIM and LWP may agree to feature any or all of each other's sites or services on an exclusive basis on a site or service specific basis, meaning that they will not feature any other substantially similar third party site or service. Sites or services that will be featured exclusively will be listed in EXHIBIT K.
General Concept. LWP agrees to support future CIM services with Talk City and OnNow integration subject to the reasonableness of doing so and CIM agrees to make a good faith effort to consider integrating future LWP services in and onto CIM Sites, subject to the reasonableness of doing so.
General Concept. CIM and LWP agree to co-market the CIM Talk City Areas and the relationship between the companies with the goal of growing these services and the two companies' other respective services and with marketing program specifics to be agreed on mutually by the two companies. LWP agrees to provide CIM and its designees with a number of advertising impressions, in accordance with the terms and conditions detailed in SECTION 3.6 PROMOTIONAL CONSIDERATION below.
General Concept. CIM and LWP shall both have rights to sell Advertising Inventory on the CIM Talk City Areas. The two companies will share in the revenue from such sales by either company.
General Concept. The two parties agree to split Advertising Inventory and share Advertising Revenue sold by either party on the CIM Talk Areas and, where applicable, the Talk City Service, the OnNow Service or areas within the Talk City Service or OnNow service containing content from Other Partners (the "Other Partner Joint Content Areas") and to share revenue from Excess Inventory as detailed herein. The two parties agree to manage the Advertising Inventory to facilitate coordination of the Advertising sales and revenue sharing.
General Concept. CIM shall have the option (the "Option"), at its discretion and upon reasonable prior notice to LWP, to substitute the following terms and conditions contained in SECTION 5 ALTERNATE RESPONSIBILITIES, GUIDELINES AND FINANCIAL TERMS below for the terms and conditions in SECTION 4 ADVERTISING INVENTORY AND REVENUE ALLOCATIONS, SALES AND OTHER FINANCIAL TERMS. CIM shall be permitted to exercise the Option or to elect to return to the terms and conditions of SECTION 4 ADVERTISING INVENTORY AND REVENUE ALLOCATIONS, SALES AND OTHER FINANCIAL TERMS no more than once in any given twelve (12) month period. If CIM does not choose to exercise the Option, then the terms and conditions contained in this SECTION 5 ALTERNATE RESPONSIBILITIES, GUIDELINES AND FINANCIAL TERMS shall have no effect or significance whatsoever.
General Concept. [*] percent ([*]%) of the Advertising Revenue sold and collected by CIM, LWP or, to the extent applicable, an Other Partner (each a "Selling Party" and collectively, the "Selling Parties") pursuant to the terms of SECTION 4.3.2 ADVERTISING INVENTORY SPLITS above, shall be retained by such Selling Party, and the remaining [*] percent ([*]%) shall be remitted to the non-Selling Party or if applicable, to the non-Selling Parties. The [*] percent ([*]%) difference between the Advertising Revenue retained by a Selling Party and a non-Selling Party shall represent consideration to the Selling Party for costs incurred in selling allocated Advertising Inventory or Excess Inventory, including but not limited to taxes, advertising agency fees and sales commissions. An illustrative table for splitting inventory, sharing revenue and calculating revenue shares by and among CIM, LWP and where applicable, Other Partners, based on the Advertising Inventory splits contemplated in SECTION 4.3.2, is attached hereto as EXHIBIT S. Advertising Revenue shares shall be calculated as follows:
General Concept. UF-VARR is contingent upon pharmaceutical agents being placed on the generic (1st tier) or formulary (2nd tier) of the DoD Uniform Formulary. Refund quotes for UF-VARRs may be submitted only for pharmaceutical agents that are scheduled for review by the DoD Pharmacy & Therapeutics (P&T) Committee at the next Committee meeting. The DoD P&T Committee will consider refund quotes for UF-VARRs as part of its evaluation of the relative cost effectiveness of pharmaceutical agents in recommending the placement of pharmaceutical agents on the DoD Uniform Formulary. Refund Quote for Inclusion on Uniform Formulary (UF)
General Concept. The Team will collaborate to secure necessary grants and funding for implementing the plans outlined in Section 3.3 of this document.
